Ferring Pharmaceuticals today announced the opening of a state-of-the-art global manufacturing hub in Finland for the drug substance of its intravesical non-replicating gene therapy Adstiladrin® (nadofaragene firadenovec-vncg). This represents a s…
– 출처 : https://www.newswire.co.kr/newsRead.php?no=998020&sourceType=rss
